Note: In this book, 15 cancer doctors share the details of their treatment protocols and answer difficult questions about cancer. Each physician is given their own chapter in the book. The page you are viewing contains sample material; to read the rest of the book, you can place your order for the book from the publisher, Amazon, or Barnes & Noble. You can also buy the Kindle Edition.
Stanislaw Burzynski, MD, PhD, (doctor’s website), is an internationally-recognized physician and biochemist-researcher who has pioneered the development and use of biologically active peptides for diagnosing, preventing, and treating cancer since 1967.
In 1967, at the young age of 24, he graduated with distinction from the Medical Academy in Lublin, Poland with an MD degree, finishing first in his class of 250. During the same year, he identified naturally-occurring peptides in the human body which he concluded controlled cancer growth. He found that there is a marked deficiency of these peptides in cancer patients.
The following year, in 1968, he earned his PhD in Biochemistry and became one of the youngest candidates in Poland to ever hold both an MD and PhD degree.
From 1970 to 1977, while a researcher and Assistant Professor at Baylor College of Medicine in Houston, his research was sponsored and partially funded by the National Cancer Institute. At Baylor, he authored and co-authored sixteen publications. Five concerned his research on peptides and their effect on human cancer, and four others were co-authored by other doctors associated with MD Anderson Hospital and Tumor Institute and Baylor College of Medicine. It was at Baylor that he named these peptides “antineoplastons” due to their activity in correcting and normalizing neoplastic or cancerous cells.
In May 1977, Dr. Burzynski received a Certificate of Appreciation from Baylor College of Medicine, commending him for five years of dedicated service to the college and acknowledging him for the contributions that he made to the “advancement of medical education, research, and health care.”
That same month, Dr. Burzynski founded his clinic in Houston, where he has since treated over 15,000 patients. He is also President of the Burzynski Research Institute, where he continues to pursue scientific research on antineoplastons.
Dr. Burzynski is a member in good standing of many renowned medical associations, including the American and World Medical Associations, American Association for Cancer Research, Society for Neuroscience, Texas Medical Association, Royal Medical Association (U.K.), and the Society for Neuro-Oncology.
Dr. Burzynski is the author and co-author of over 300 scientific publications and presentations. Throughout his career, he has received numerous prestigious awards from various medical, educational, and governmental institutions. As of January 2007, he holds 242 patents related to proprietary scientific inventions.
Other groups of scientists have expanded Dr. Burzynski’s work, including researchers at the University of Kurume Medical School in Japan. Several hundred publications on antineoplastons and their active ingredients have been written by scientists who work independently of the Burzynski Research Institute.
What Cancer Is, What Causes It, and How to Treat It
Cancer can be defined as the uncontrolled growth of abnormal cells, which is caused by cancer genomes (a genome is all the genetic material contained in an organism, including its DNA, or deoxyribonucleic acid). The cancer genome is a special combination of genes which conspires to produce cells that successfully compete for survival with normal cells of the body, and which are able to survive better than these normal cells. Scientists have now identified genomes for about 100 different types of cancer, so they can tell how many genes are abnormal in various types of cancers and what those specific genes are. Modern scientists are finally accepting that it’s the abnormal, malignant genomes which cause cancer and that these genomes are more complex than normal genomes. Cancer genomes are very complicated and there is much we have yet to understand about them. There are multiple factors which cause abnormal genomes to develop, but it’s a very difficult task to try to identify what all of these are.
Regardless of the factors that trigger the development of cancer, in order to effectively treat it, doctors must identify and then control the abnormal genes that are causing it. This is a very difficult task, since the average cancer has about 80 abnormal genes but can have over 500 abnormal genes. The average number of abnormal genes involved in most people’s cancers ranges from 40 to 200. These abnormal genes hijack and suffocate a much larger number of normal genes—approximately 600-1,000.
In addition to normal genes, the body also has silent genes; that is, genes that have been switched off (by environmental and other factors), and which no longer help the body to protect itself against cancer. Turning these silent tumor-suppressor genes back on again is very important for defeating cancer.
So, controlling gene expression is a complex task, made even more difficult by the fact that the 80 or so abnormal genes that cause cancer can end up creating a deregulated network of over 3,000 genes in the body—all of which cause and spread malignant disease.
Order your copy of the book to finish reading this chapter. The following are additional sections contained in this chapter:
- Antineoplastons for Controlling Cancer Cells
- How I Discovered Antineoplastons
- Using Antineoplastons and Gene-Targeted Therapy to Treat Cancer
- Treatment Process
- Types of Antineoplastic and Gene-Targeted Medications
- Use of Antineoplastons for Other Diseases
- Dietary and Supplement Recommendations
- Preventing Cancer with Supplements
- Treatment Outcomes
- Training Other Doctors to Use Antineoplastons
- Improving Cancer Care
- The Problem with Conventional Oncology
- When to Use Conventional Medicine to Treat Cancer
- Side Effects of Gene-Targeted Therapies
- Other Factors That Affect Patients’ Healing
- How Family and Friends Can Support Their Loved Ones with Cancer
- Roadblocks to Healing
- Insurance Coverage for Treatments
- The Politics of Cancer Treatment in the United States and My Battle with the FDA
- The Future of Cancer Treatment
- Last Words
- Useful Websites
- Last Words
Buy the book to finish reading this chapter.